Plus Therapeutics Appoints Randy Goodman As Vice President To Lead HEOR And Market Access Strategy

Plus Therapeutics has announced the appointment of Randy H. Goodman, Ph.D., M.H.A., as Vice President, Value Strategy & Health Economics and Outcomes Research (HEOR), effective April 13, 2026. The appointment strengthens the company’s capabilities in market access and value-based healthcare as it advances its CNS oncology portfolio.

Dr. Goodman brings over 20 years of experience in global pricing, reimbursement strategy, real-world evidence generation, and health economics. He has led payer engagement initiatives, developed health technology assessment (HTA) dossiers, and supported commercialization strategies across the biotechnology, pharmaceutical, diagnostics, and medical device sectors.

“Randy brings a rare combination of deep HEOR expertise, payer strategy experience, and health policy insight that will be critical as we continue to expand access and adoption of CNSide and advance our therapeutic pipeline,” said Marc Hedrick, M.D., MBA, Plus Therapeutics President and Chief Executive Officer. “His leadership will strengthen our ability to clearly demonstrate the clinical and economic value of our technologies to payers, providers, and policymakers.”

Throughout his career, he has advised major healthcare companies such as Pfizer, Gilead Sciences, and Moderna, and has collaborated with government bodies including the Centers for Medicare & Medicaid Services. He also served as a healthcare policy advisor to the White House, contributing to reimbursement and access frameworks at both federal and state levels.

“Demonstrating clinical and economic value is increasingly critical to successful adoption of medical innovation,” said Dr. Goodman. “CNSide and REYOBIQ represent highly differentiated technologies, and I look forward to helping ensure that their value is clearly articulated and recognized across the healthcare system.”

In his new role, Dr. Goodman will lead Plus Therapeutics’ value strategy, HEOR, and market access efforts. His work will support the commercial expansion of CNSide Diagnostics and help build the evidence and reimbursement foundation for REYOBIQ and the company’s broader CNS oncology pipeline.